uniQure NV
Closed
29.1 5.47
Overview
Share price change
24h
Min
26.99
Max
29.77
Income | -16M -54M |
|---|---|
Sales | -2M 3.6M |
EPS | -0.727 |
Profit margin | -1,502.948 |
Employees | 221 |
EBITDA | 13M -36M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +40.38% upside |
Next Earnings | 28 Jul 2026 |
|---|
Market Cap | 440M 1.7B |
|---|---|
Previous open | 23.63 |
Previous close | 29.1 |
Technical Score
By Trading Central
Confidence
Strong Bearish Evidence
uniQure NV Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
uniQure NV Forecast
Price Target
By TipRanks
40.38% upside
12 Months Forecast
Average 38.8 USD 40.38%
High 95 USD
Low 9 USD
Based on 12 Wall Street analysts offering 12 month price targets foruniQure NV - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About uniQure NV
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
